CA2288222A1 - Oligonucleotide mediated specific cytokine induction and in vivo protection from infection - Google Patents
Oligonucleotide mediated specific cytokine induction and in vivo protection from infection Download PDFInfo
- Publication number
- CA2288222A1 CA2288222A1 CA002288222A CA2288222A CA2288222A1 CA 2288222 A1 CA2288222 A1 CA 2288222A1 CA 002288222 A CA002288222 A CA 002288222A CA 2288222 A CA2288222 A CA 2288222A CA 2288222 A1 CA2288222 A1 CA 2288222A1
- Authority
- CA
- Canada
- Prior art keywords
- mammal
- phosphodiester
- phosphorothioate
- oligonucleotide
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
Abstract
The invention provides methods for modulating specific CMI-inducing cytokines in vivo. Such methods result in stimulation of the cytokines IL-6, IL-12 MIP-1.beta. and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon administration of oligonucleotides containing particular structural motifs which lead to specific cytokine induction.
Claims (9)
1. A method for elevating serum levels of IL-12 in a mammal, including a human, the method comprising measuring a baseline level of IL-12 in the mammal, administering to the mammal an oligonucleotide having a structural motif which induces IL-12 expression in vivo, and measuring the level of IL-12 in the mammal after such administration, wherein the level of IL-12 measured after such administration is higher than the level of IL-12 measured before such administration.
2. The method according to claim 1, wherein the oligonucleotide has the nucleotide sequence N n1,-Nn2-CpG-Nn3-N n4, wherein N represents any nucleoside, n1 and n4 each independently represent a number from 0 to 50, n2 represents a number from 0 to 50 and n3 represents a number from 0 to 50 such that n2 + n3 equals from about 6 to about 100, wherein the underlined region represents a nucleoside phosphodiester or phosphorothioate region or a mixed backbone region having phosphodiester and phosphorothioate nucleosides, wherein CpG represents a cytosine-guanosine dinucleoside phosphorothioate or phosphodiester dinucleoside, wherein the cytosine has a cytidine base having an unmethylated 5-position, and wherein at least one of n1, n2, n3 and n4 comprises four contiguous guanosine nucleosides.
3. A method for elevating expression of IL-12 mRNA in a mammal, the method comprising measuring a baseline level of IL-12 mRNA in cells from the mammal, administering to the mammal an oligonucleotide having a structural motif which induces IL-12 expression in vivo, and measuring the level of IL-12 mRNA in cells from the mammal after such administration, wherein the level of IL-12 mRNA measured after such administration is higher than the level of IL-mRNA measured before such administration.
4. A method for prophylactically protecting a mammal from infection by a pathogen, the method comprising administering to a mammal which is not expressing symptoms of infection by the pathogen an oligonucleotide having a structural motif which induces IL-12 expression in vivo in an amount and for a time sufficient to prevent successful infection by the pathogen.
5. The method according to claim 4, wherein the oligonucleotide has the nucleotide sequence N n1-Nn2-CpG-Nn3-N n4, wherein N represents any nucleoside, n1 and n4 each independently represent a number from 0 to 50, n2 represents a number from 0 to 50 and n3 represents a number from 0 to 50 such that n2 + n3 equals from about 6 to about 100, wherein the underlined region represents a nucleoside phosphodiester or phosphorothioate region or a mixed backbone region having phosphodiester and phosphorothioate nucleosides, wherein CpG represents a cytosine-guanosine dinucleoside phosphorothioate or phosphodiester dinucleoside, wherein the cytosine has a cytidine base having an unmethylated 5-position, and wherein at least one of n1, n2, n3 and n4 comprises four contiguous guanosine nucleosides.
6. A method for therapeutically treating a mammal which is infected by a pathogen, the method comprising administering to the infected animal an oligonucleotide having a structural motif which induces IL-12 expression in vivo in an amount and for a time sufficient to eliminate or reduce symptoms of infection by the pathogen.
7. The method according to claim 6, wherein the oligonucleotide has the nucleotide sequence N n1-Nn2-CpG-Nn3-N n4, wherein N represents any nucleoside, n1 and n4 each independently represent a number from 0 to 50, n2 represents a number from 0 to 50 and n3 represents a number from 0 to 50 such that n2 + n3 equals from about 6 to about 100, wherein the underlined region represents a nucleoside phosphodiester or phosphorothioate region or a mixed backbone region having phosphodiester and phosphorothioate nucleosides, wherein CpG represents a cytosine-guanosine dinucleoside phosphorothioate or phosphodiester dinucleoside, wherein the cytosine has a cytidine base having an unmethylated 5-position, and wherein at least one of n1, n2, n3 and n4 comprises four contiguous guanosine nucleosides.
8. A method for reducing tumor growth in a mammal which has a tumor, the method comprising administering to a mammal having a tumor an oligonucleotide having a structural motif which induces IL-12 expression in vivo in an amount and for a time sufficient to eliminate or reduce tumor growth.
9. The method according to claim 8, wherein the oligonucleotide has the nucleotide sequence N n1,-Nn2-CpG-Nn3-N n4, wherein N represents any nucleoside, n1 and n4 each independently represent a number from 0 to 50, n2 represents a number from 0 to 50 and n3 represents a number from 0 to 50 such that n2 + n3 equals from about 6 to about 100, wherein the underlined region represents a nucleoside phosphodiester or phosphorothioate region or a mixed backbone region having phosphodiester and phosphorothioate nucleosides, wherein CpG represents a cytosine-guanosine dinucleoside phosphorothioate or phosphodiester dinucleoside, wherein the cytosine has a cytidine base having an unmethylated 5-position, and wherein at least one of n1, n2, n3 and n4 comprises four contiguous guanosine nucleosides.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/848,229 US6426334B1 (en) | 1997-04-30 | 1997-04-30 | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
US08/848,229 | 1997-04-30 | ||
PCT/US1998/008751 WO1998049288A1 (en) | 1997-04-30 | 1998-04-30 | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2288222A1 true CA2288222A1 (en) | 1998-11-05 |
CA2288222C CA2288222C (en) | 2011-06-21 |
Family
ID=25302725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2288222A Expired - Fee Related CA2288222C (en) | 1997-04-30 | 1998-04-30 | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
Country Status (7)
Country | Link |
---|---|
US (2) | US6426334B1 (en) |
EP (2) | EP1408110B1 (en) |
JP (1) | JP2002505666A (en) |
AT (1) | ATE512221T1 (en) |
AU (1) | AU7171298A (en) |
CA (1) | CA2288222C (en) |
WO (1) | WO1998049288A1 (en) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
JP4359654B2 (en) * | 1996-01-30 | 2009-11-04 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Gene expression vector for generating antigen-specific immune response and method of use thereof |
NZ508650A (en) * | 1998-05-14 | 2003-05-30 | Coley Pharm Gmbh | Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification |
DE69932717T2 (en) * | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
JP2002536344A (en) * | 1999-02-05 | 2002-10-29 | ジエンザイム コーポレイション | Use of cationic lipids to generate anti-tumor immunity |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
PT1154790E (en) * | 1999-02-26 | 2005-03-31 | Chiron Srl | REFORCO OF THE ACTIVITY BACTERICIDE OF ANTIGEN AGAINST NEISSERIA WITH OLIGONUCLEOTIDOS CONTAINING REASONS CG |
ES2541830T3 (en) | 1999-10-29 | 2015-07-27 | Novartis Vaccines And Diagnositics S.R.L. | Neisseria antigenic peptides |
EP1322655B1 (en) | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6815429B2 (en) | 2000-01-26 | 2004-11-09 | Hybridon, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
ES2238044T3 (en) * | 2000-05-01 | 2005-08-16 | Hybridon, Inc. | MODULATION OF IMMUNOLOGICAL STIMULATION MEDIATED BY THE CPG OLIGONUCLEOTIDE BY POSITIONAL MODIFICATION OF NUCLEOSIDS. |
JP2008531580A (en) * | 2000-12-08 | 2008-08-14 | スリーエム イノベイティブ プロパティズ カンパニー | Compositions and methods for targeted delivery of immune response modifiers |
US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
CN100334228C (en) | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | Cimeric immunomodulatory compounds and methods of using the same |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
WO2003014316A2 (en) * | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
SI1446162T1 (en) | 2001-08-17 | 2009-04-30 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
DK1719511T3 (en) * | 2001-11-16 | 2009-04-14 | Coley Pharm Group Inc | N- [4- (4-amino-2-ethyl-1H-imidazo [4,5-c] quinolin-1-yl) butyl] methanesulfonamide, a pharmaceutical composition comprising the same, and use thereof |
CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
JP2005518433A (en) * | 2002-02-22 | 2005-06-23 | スリーエム イノベイティブ プロパティズ カンパニー | Methods for reducing and treating UVB-induced immunosuppression |
KR100456681B1 (en) * | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | Immnune-stimulating and controlling Composition comprising bacterial chromosomal DNA fragments and detoxified lipopolysaccharides |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003299863B2 (en) | 2002-08-15 | 2009-09-24 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
MXPA05004588A (en) | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection. |
AU2003287316A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
AU2003287324A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
AU2003300919A1 (en) | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
CN100546998C (en) | 2002-12-23 | 2009-10-07 | 戴纳伐克斯技术股份有限公司 | Immunostimulatory sequence oligonucleotides and using method |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
US7851453B2 (en) | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
WO2004071459A2 (en) * | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
US7485432B2 (en) * | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
AU2004218349A1 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
CA2518445A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
MXPA05009694A (en) * | 2003-03-13 | 2005-10-20 | 3M Innovative Properties Co | Methods of improving skin quality. |
US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
AU2004244962A1 (en) * | 2003-04-10 | 2004-12-16 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
AU2004241093B2 (en) * | 2003-05-16 | 2009-08-27 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
AU2004259204B2 (en) | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
RU2006102188A (en) * | 2003-07-31 | 2006-07-10 | ЗМ Инновейтив Пропертиз Компани (US) | BIOACTIVE COMPOSITIONS INCLUDING TRIAZINES |
WO2005016273A2 (en) * | 2003-08-05 | 2005-02-24 | 3M Innovative Properties Company | Infection prophylaxis using immune response modifier compounds |
JP2007502288A (en) | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | Oxime-substituted imidazo-containing compounds |
EP1660122A4 (en) * | 2003-08-25 | 2007-10-24 | 3M Innovative Properties Co | Immunostimulatory combinations and treatments |
AU2004268616B2 (en) * | 2003-08-25 | 2010-10-07 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
EP1658076B1 (en) | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
JP2007504172A (en) * | 2003-09-02 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Methods for treatment of mucosa related symptoms |
AU2004270201A1 (en) * | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
BRPI0414856A (en) | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | alkoxy-substituted imidazoquinolines |
WO2005034979A2 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
CA2540949A1 (en) | 2003-10-30 | 2005-05-12 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
WO2005041891A2 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
WO2005048945A2 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
CA2545774A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8940755B2 (en) * | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
WO2005060377A2 (en) | 2003-12-08 | 2005-07-07 | Hybridon, Inc. | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
US8735421B2 (en) | 2003-12-30 | 2014-05-27 | 3M Innovative Properties Company | Imidazoquinolinyl sulfonamides |
EP1699398A4 (en) * | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | Enhancement of immune responses |
WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
JP2008505857A (en) * | 2004-04-28 | 2008-02-28 | スリーエム イノベイティブ プロパティズ カンパニー | Compositions and methods for mucosal vaccination |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
HUE026644T2 (en) | 2004-05-28 | 2016-07-28 | Oryxe | A mixture for transdermal delivery of low and high molecular weight compounds |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
EP1786450A4 (en) * | 2004-08-27 | 2009-11-11 | 3M Innovative Properties Co | Hiv immunostimulatory compositions |
WO2006042254A2 (en) * | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
CA2594674C (en) | 2004-12-30 | 2016-05-17 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
ES2538498T3 (en) | 2004-12-30 | 2015-06-22 | Meda Ab | Use of Imiquimod for the treatment of skin metastases from a breast cancer tumor |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US7968563B2 (en) | 2005-02-11 | 2011-06-28 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
JP2008539252A (en) * | 2005-04-25 | 2008-11-13 | スリーエム イノベイティブ プロパティズ カンパニー | Immune activation composition |
ATE476193T1 (en) | 2005-07-01 | 2010-08-15 | Index Pharmaceuticals Ab | IMMUNO-STIMULATORY PROCEDURE |
DK2179737T3 (en) | 2005-07-01 | 2013-11-11 | Index Pharmaceuticals Ab | MODULE RESPONSE ON STEROIDS |
NZ565311A (en) * | 2005-07-07 | 2009-10-30 | Pfizer | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
US8426375B2 (en) * | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
US8399423B2 (en) * | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
US8383598B2 (en) * | 2005-10-12 | 2013-02-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
WO2007047396A2 (en) | 2005-10-12 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
AU2006306805A1 (en) * | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US7776834B2 (en) * | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP2371956A3 (en) | 2005-11-07 | 2012-01-04 | Idera Pharmaceuticals | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP3085373A1 (en) | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Immune response modifier conjugates |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
CA2694973A1 (en) * | 2007-08-15 | 2009-02-19 | Idera Pharmaceuticals, Inc. | Toll like receptor modulators |
JP2012505221A (en) * | 2008-10-06 | 2012-03-01 | イデラ ファーマシューティカルズ インコーポレイテッド | Use of inhibitors of Toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and related diseases |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2011005942A2 (en) | 2009-07-08 | 2011-01-13 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
AU2010284329B2 (en) * | 2009-08-18 | 2015-04-16 | Takeda Pharmaceutical Company Limited | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
CA2817891C (en) | 2010-11-19 | 2021-10-12 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
JP6002691B2 (en) | 2011-02-11 | 2016-10-05 | バクスアルタ ゲーエムベーハー | Aptamers for tissue factor pathway inhibitors and their use as therapeutic agents for bleeding disorders |
CA2838023C (en) | 2011-06-03 | 2019-08-13 | 3M Innovative Properties Company | Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom |
JP6460789B2 (en) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
EP2596806A1 (en) | 2011-11-25 | 2013-05-29 | Index Pharmaceuticals AB | Method for prevention of colectomy |
KR101898177B1 (en) | 2013-01-08 | 2018-09-12 | 이데라 파마슈티칼즈, 인코포레이티드 | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
EP3632458A1 (en) | 2013-07-26 | 2020-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
EP3349717A4 (en) | 2015-09-17 | 2019-04-17 | JRX Biotechnology, Inc. | Approaches for improving skin hydration or moisturization |
US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
KR20200128116A (en) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | IL-15 variants and uses thereof |
CA3100829A1 (en) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
EP3797121A1 (en) | 2018-05-23 | 2021-03-31 | Pfizer Inc | Antibodies specific for cd3 and uses thereof |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
MX2022006578A (en) | 2019-12-17 | 2022-07-04 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof. |
JP2023533793A (en) | 2020-07-17 | 2023-08-04 | ファイザー・インク | Therapeutic antibodies and their uses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ES2267100T5 (en) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | IMMUNOMODULATING OLIGONUCLEOTIDES. |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
-
1997
- 1997-04-30 US US08/848,229 patent/US6426334B1/en not_active Expired - Fee Related
-
1998
- 1998-04-30 AT AT04000457T patent/ATE512221T1/en not_active IP Right Cessation
- 1998-04-30 JP JP54739598A patent/JP2002505666A/en active Pending
- 1998-04-30 EP EP04000457A patent/EP1408110B1/en not_active Expired - Lifetime
- 1998-04-30 EP EP98918873A patent/EP0991755A1/en not_active Withdrawn
- 1998-04-30 AU AU71712/98A patent/AU7171298A/en not_active Abandoned
- 1998-04-30 WO PCT/US1998/008751 patent/WO1998049288A1/en not_active Application Discontinuation
- 1998-04-30 CA CA2288222A patent/CA2288222C/en not_active Expired - Fee Related
-
2002
- 2002-06-12 US US10/167,825 patent/US7700570B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE512221T1 (en) | 2011-06-15 |
EP1408110A3 (en) | 2007-10-31 |
JP2002505666A (en) | 2002-02-19 |
EP0991755A1 (en) | 2000-04-12 |
EP1408110A2 (en) | 2004-04-14 |
WO1998049288A1 (en) | 1998-11-05 |
EP1408110B1 (en) | 2011-06-08 |
US20020151518A1 (en) | 2002-10-17 |
AU7171298A (en) | 1998-11-24 |
US6426334B1 (en) | 2002-07-30 |
US7700570B2 (en) | 2010-04-20 |
CA2288222C (en) | 2011-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2288222A1 (en) | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection | |
ES2267100T3 (en) | IMMUNOMODULATOR OLIGNUCLEOTIDES. | |
EP1252307B1 (en) | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES | |
US6476000B1 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
EP2360252B1 (en) | Immunostimulatory nucleic acid molecules comprising GTCGTT motifs | |
EP1278761B1 (en) | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES | |
US6653292B1 (en) | Method of treating cancer using immunostimulatory oligonucleotides | |
US7176296B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
RU2004132209A (en) | IMMUNITY MULTI-G, U-CONTAINING OLIGORIBONUCLEOTIDES | |
US7105495B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides | |
KR20030061812A (en) | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | |
Mannon et al. | Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides | |
EP1496121A2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140430 |